Every Form 4 that Akari Therapeutics plc (AKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics Plc (AKTX) director Raymond Prudo-Chlebosz was granted 9,072 American Depositary Shares (ADSs) representing restricted stock units on August 18, 2026, and 3,240 ADSs on October 5, 2026, in lieu of accrued but unpaid cash retainers payable to non-executive directors. Both RSU awards are subject to forfeiture if shareholder approval of a proposed amendment increasing shares reserved under the equity incentive plan is not obtained, and vest in full on approval. He was also granted options for 30,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.899 exercise price; vesting depends on approval and continued service.
Akari Therapeutics Plc reported direct awards to director and 10% owner Hoyoung Huh: an RSU award reported for 17,249 ADSs on August 18, 2026, and one for 6,160 ADSs on October 5, 2026. Both were granted in lieu of accrued but unpaid cash retainers payable to directors, are subject to forfeiture if Shareholder Approval of a proposed equity incentive plan amendment to increase the plan’s share reserve is not obtained, and vest in full on the approval date. On August 18, 2026, Huh also received options covering 30,000 ADSs and 15,000 ADSs, each with a $7.8990 exercise price and subject to the same approval condition. The options have different vesting schedules, require continued service on each vesting date, and expire August 18, 2036.
Akari Therapeutics Plc (AKTX) director Sandip I. Patel reported exercising pre-funded warrants covering 3,866 ADSs and 6,186 ADSs on October 14, 2026, at an exercise price of $0.0004 per ADS. He also reported awards of RSUs representing 12,100 ADSs on August 18, 2026, and 4,313 ADSs on October 5, 2026, granted in lieu of accrued but unpaid cash retainers under the issuer’s remuneration policy. The RSUs are subject to forfeiture if shareholder approval of a proposed equity-plan amendment is not obtained and vest in full upon approval. Patel also received options to purchase 45,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.8990 exercise price and an expiration date of August 18, 2036. Both option grants are subject to forfeiture if shareholder approval is not obtained and have separate vesting schedules.
Akari Therapeutics Plc director Robert B. Bazemore reported exercising pre-funded warrants for 773 and 3,093 ADSs on October 14, 2026, acquiring corresponding American Depositary Shares at an exercise price of $0.0004 per ADS; the related warrant positions were reported as disposed. The warrants became exercisable upon shareholder approval obtained March 2, 2026.
He also received awards of 13,100 ADSs representing restricted stock units on August 18, 2026, and 4,677 ADSs representing restricted stock units on October 5, 2026. The RSUs were granted in lieu of accrued but unpaid cash retainers in accordance with the Company's remuneration policy. They will vest in full upon shareholder approval of a proposed equity incentive plan amendment and are subject to forfeiture if approval is not obtained. On August 18, 2026, he also received options to purchase 45,000 and 15,000 ADSs, each with a $7.899 exercise price and an August 18, 2036 expiration date; those options are also subject to forfeiture if approval is not obtained.
Akari Therapeutics Plc CEO Abizer Gaslightwala exercised pre-funded warrants on October 14, 2026, acquiring 19,333 ADSs and 7,733 ADSs at an exercise price of $0.0004 per ADS. The warrants became exercisable upon shareholder approval obtained March 2, 2026. On August 18, 2026, he was granted options to purchase 174,000 ADSs at $7.899 per ADS, expiring August 18, 2036; the grant is subject to forfeiture if shareholder approval of a proposed equity-plan amendment is not obtained, and vesting is subject to continued service.
Akari Therapeutics Plc director Samir Rashmikant Patel received 6,300 ADSs as RSUs on August 18, 2026, and 2,236 ADSs on October 5, 2026; both were granted in lieu of accrued but unpaid cash retainers. The RSUs and options are subject to forfeiture if shareholders do not approve a proposed equity-plan amendment; RSUs vest in full upon approval. On August 18, Patel received options for 30,000 and 15,000 ADSs, each exercisable at $7.8990 per ADS and expiring August 18, 2036; option vesting also requires approval and continued service.
Akari Therapeutics Plc (AKTX) Chief Business Officer Vat-Ho Vatnak received an option grant to purchase 87,000 ADSs. The award transaction is dated October 12, 2026; the stated Grant Date is October 5, 2026. The options have an exercise price of $8.94 per ADS and are subject to forfeiture and cancellation if shareholders do not approve a proposed increase in the equity plan’s share reserve. They vest 25% on the Grant Date’s 12-month anniversary, then in equal monthly installments over the next 36 months, subject to continued service, with full vesting on the 4-year anniversary.
Akari Therapeutics Plc CEO Abizer Gaslightwala received a direct award of 6,430 American Depositary Shares representing ordinary shares on September 29, 2026, at a reported $9.72 per share; his reported direct holdings afterward were 14,107 shares. The associated RSUs vest in four approximately equal quarterly installments, subject to continued service, and are subject to forfeiture and cancellation if shareholders do not approve an amendment increasing the equity incentive plan's share reserve.
Akari Therapeutics Plc (symbol: AKTX) is the issuer of record for a Form 4 filing submitted to the SEC.
Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.
Akari Therapeutics Plc reported that interim CFO Farag Kameel D. received a grant of 1,130 American Depositary Shares representing restricted stock units on July 16, 2026, at a reported price of $11.50 per share. According to the footnote, these ADSs represent RSUs, with each RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, and the RSUs will vest in full on August 16, 2026. Following this award, the interim CFO directly owns 21,581 ADSs.
Akari Therapeutics Plc director and 10% owner Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026 to acquire 22,474 American Depositary Shares (ADSs). These exercises delivered 5,799 and 15,466 ADSs at $0.0004 per ADS and 1,209 ADSs at $8.00 per ADS. The related pre-funded warrant positions reported were reduced to zero, and the transactions are not designated as occurring under a Rule 10b5-1 trading plan. Each ADS represents 80,000 ordinary shares.
Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.
Akari Therapeutics Plc interim CFO Farag Kameel D. received share awards in the form of American Depositary Shares (ADSs) representing ordinary shares. On June 24, 2026, multiple grant/award transactions (code A) increased his direct ADS holdings to 20,452 shares.
A footnote explains these ADS-related awards represent restricted stock units (RSUs), with each RSU giving the right to receive 80,000 ordinary shares. The RSUs vested in full on June 24, 2026, indicating these grants are compensation-related rather than open‑market purchases.
Akari Therapeutics CEO Abizer Gaslightwala reported new stock option awards. On April 1, 2026 he was granted options over 15,563 American Depositary Shares at an exercise price of $14.63 per ADS and options over 5,500 ADS at $4.64 per ADS. Each ADS represents 80,000 ordinary shares. These awards were compensation-related grants rather than open-market share purchases or sales.
Akari Therapeutics director Neal James increased his economic exposure to the company on December 16, 2025 by acquiring derivative securities tied to its American Depositary Shares (ADSs).
He obtained a total of 11,132 warrants and pre-funded warrants to purchase ADSs through a private placement and a note cancellation and exchange agreement. The PIPE pre-funded warrants and accompanying Series G Warrants, as well as additional note-exchange warrants, are exercisable only upon shareholder approval. The pre-funded warrants carry a stated conversion exercise price of $0.00001 per ADS.
Akari Therapeutics (AKTX) reported an insider equity grant by its Interim CFO. On 11/01/2025, the officer acquired 32,000 and 26,619 American Depositary Shares (ADS) at $0.75 per ADS. The filing lists post‑transaction beneficial ownership of 32,000 and 26,619 ADS, held directly.
These ADSs represent restricted stock units (RSUs) that vest on January 1, 2026 and February 15, 2026. Each ADS represents 2,000 ordinary shares.